news
Urothelial cancer drug Enfortumab Vedotin works better for women
New research presented at the German Society of Urology congress shows that women with advanced urothelial carcinoma treated with Enfortumab Vedotin (EV) experience longer progression-free survival than men. Annemarie Uhlig from Tübingen University Hospital reported that while overall survival was similar, women's disease progression was significantly slowed. This suggests a potential sex-specific drug response in advanced cancer treatment.
New research presented at the German Society of Urology congress shows that women with advanced urothelial carcinoma treated with Enfortumab Vedotin (EV) experience longer progression-free survival than men. Annemarie Uhlig from Tübingen University Hospital reported that while overall survival was similar, women's disease progression was significantly slowed. This suggests a potential sex-specific drug response in advanced cancer treatment.
The architecture take
This finding, while specific to urothelial cancer, is a stark reminder that 'one size fits all' in medicine is just lazy. We're still uncovering the nuances of how drugs interact with different bodies, and sex — meaning biological sex, not gender identity — clearly plays a role here. Longer progression-free survival for women suggests the drug's mechanism, an antibody-drug conjugate, might be more effective in female physiology or tumor biology. I'm always looking for this kind of granularity. It's not enough to say a drug works; we need to know for whom and why. This research pushes us toward truly personalized medicine, acknowledging the biological differences that exist beyond simple disease classification. It's the kind of detail that could shift treatment protocols globally, not just in Germany. My take? Demand to know the sex-disaggregated data on any treatment you're considering. It matters.